The first children have been vaccinated in Moderna's Phase 2/3 pediatric COVID-19 vaccine trial, the company announced Tuesday in a statement.
The trial is broken into two parts. In part one, different dosages of the vaccine are being tested on the children. Children between the ages of 6 months and 1 year old will receive two doses of the vaccine spaced about 28 days apart at either a 25 or a 50 or a 100 microgram level. Children between the ages of 2 and 11 will receive two doses of the vaccine spaced about 28 days apart at either a 50 or a 100 microgram level.
Moderna is doing the tests to see if the vaccine protects children from getting sick if they come into contact with coronavirus, according to the clinical trial's patient information website. The study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, and the Biomedical Advanced Research and Development Authority at the US Department of Health and Human Services.